CDTX Cidara Therapeutics Inc

USD 11.74 -0.07 -0.592718
Icon

Cidara Therapeutics Inc (CDTX) Stock Analysis and Price Targets

COMMON STOCK | Biotechnology | NSD
stockTargetAdvisor

Strong Buy

Average Analyst
Rating
stockTargetAdvisor

Strong Buy

Top Analyst
Rating
stockTargetAdvisor

Bearish

Stock Target Advisor
Analysis
stockTargetAdvisor

N/A

Average User
Rating

USD 11.74

-0.07 (-0.59)%

USD 0.05B

0.02M

USD 24.00(+104.43%)

N/A

Icon

CDTX

Cidara Therapeutics Inc (USD)
COMMON STOCK | NSD
USD 11.74
0.00 0
Take a Tour
stockTargetAdvisor

Strong Buy

Average Analyst
Rating
stockTargetAdvisor

Strong Buy

Top Analyst
Rating
stockTargetAdvisor

Bearish

Stock Target Advisor
Analysis
stockTargetAdvisor

N/A

Average User
Rating

USD 0.05B

N/A

USD 11.74

Cidara Therapeutics Inc (CDTX) Stock Forecast

Show ratings and price targets of :
USD 24.00
(+104.43%)

Based on the Cidara Therapeutics Inc stock forecast from 3 analysts, the average analyst target price for Cidara Therapeutics Inc is USD 24.00 over the next 12 months. Cidara Therapeutics Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Cidara Therapeutics Inc is Bearish, which is based on 2 positive signals and 7 negative signals. At the last closing, Cidara Therapeutics Inc’s stock price was USD 11.74. Cidara Therapeutics Inc’s stock price has changed by -6.08% over the past week, +1.03% over the past month and -44.62% over the last year.

No recent analyst target price found for Cidara Therapeutics Inc
No recent average analyst rating found for Cidara Therapeutics Inc

Company Overview Cidara Therapeutics Inc

Cidara Therapeutics, Inc., a biotechnology company, focuses on developing targeted therapies for patients facing cancers and other serious diseases. The company's product includes rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and ...Read More

https://www.cidara.com

6310 Nancy Ridge Drive, San Diego, CA, United States, 92121

69

December

USD

USA

Adjusted Closing Price for Cidara Therapeutics Inc (CDTX)

Loading...

Unadjusted Closing Price for Cidara Therapeutics Inc (CDTX)

Loading...

Share Trading Volume for Cidara Therapeutics Inc Shares

Loading...

Compare Performance of Cidara Therapeutics Inc Shares

Symbol Capital Gain Dividend Return Total Return
Loading...
Loading...

Technical Indicators for CDTX

Assets

Top Holdings

Top Sectors

Top Regions

Stocks Similar To Cidara Therapeutics Inc (Sector: Biotechnology )

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX
Vertex Pharmaceuticals Inc +4.34 (+0.88%) USD126.85B 31.94 20.00

ETFs Containing CDTX

Symbol Name CDTX's Weight Expense Ratio Price(Change) Market Cap
no data

Frequently Asked Questions About Cidara Therapeutics Inc (CDTX) Stock

Based on ratings from 3 analysts Cidara Therapeutics Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bearish. The stock has 4 buy, sell and hold ratings.

Unfortunately we do not have enough data on CDTX's stock to indicate if its a good dividend stock.

Based on targets from 3 analysts, the average taret price for CDTX is USD 24.00 over the next 12 months. The maximum analyst target price is USD 40 while the minimum anlayst target price is USD 6.

Unfortunately we do not have enough data on CDTX's stock to indicate if its overvalued.

The last closing price of CDTX's stock was USD 11.74.

The most recent market capitalization for CDTX is USD 0.05B.

Based on targets from 3 analysts, the average taret price for CDTX is projected at USD 24.00 over the next 12 months. This means that CDTX's stock price may go up by +104.43% over the next 12 months.

We can't find any ETFs which contains Cidara Therapeutics Inc's stock.

As per our most recent records Cidara Therapeutics Inc has 69 Employees.

Cidara Therapeutics Inc's registered address is 6310 Nancy Ridge Drive, San Diego, CA, United States, 92121. You can get more information about it from Cidara Therapeutics Inc's website at https://www.cidara.com.
Heading 1 Heading 2 Heading 3 Heading 4 Heading 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5

Stock Target Advisor's Analysis

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

Icon
What to like

Icon
What not to like

Loading...